Vaccines Emerge as Powerful Tool in Kenya’s Fight Against Drug-Resistant Infections
Kenya is stepping up efforts to combat the growing threat of antimicrobial resistance (AMR), with experts now highlighting vaccines as a critical line of defense in reducing drug-resistant infections.
During the launch of a new policy brief and report titled “The Value of Vaccines to Address Antimicrobial Resistance in Kenya,” health experts called for increased investment and wider deployment of vaccines to curb the alarming rise of infections that no longer respond to treatment.
Antimicrobial resistance—commonly known as antibiotic resistance—occurs when bacteria, viruses, fungi, and parasites evolve over time and become resistant to medicines designed to kill them. This makes infections harder to treat, increases the risk of disease spread, severe illness, and death, and threatens decades of medical progress. Globally, AMR has already been linked to more than one million deaths, underscoring the urgency of the crisis.
In Kenya, the situation is worsened by the overuse and misuse of antibiotics in both human health and agriculture, creating an environment where resistant microbes can thrive and spread rapidly.
However, new findings from the Global Antibiotic Resistance Partnership (GARP) Technical Working Group, in collaboration with the Kenya Medical Research Institute (KEMRI) and the One Health Trust, point to vaccines as a highly effective solution.
“Vaccines prevent infections before they occur, reducing the need for antibiotics and ultimately slowing the development of resistance,” the report notes. This preventive approach not only protects individuals but also eases the burden on families and the healthcare system.
Kenya’s success with the pneumococcal conjugate vaccine offers a strong example. Since its introduction, infections caused by penicillin-resistant pneumococcal strains have dropped significantly, while cases of invasive pneumococcal disease have declined by over 90 percent among children under five.
Similarly, the malaria vaccine has demonstrated promising results, reducing cases by more than a third among young children in some regions. The recently introduced typhoid conjugate vaccine is also expected to significantly cut down cases of drug-resistant typhoid, particularly among children aged between nine months and 15 years.
Experts now warn that scaling up vaccine access, strengthening immunization programs, and promoting awareness will be key in sustaining these gains and preventing a future where common infections become untreatable.
As Kenya continues to confront the AMR challenge, the message from health experts is clear: investing in vaccines today could save millions of lives tomorrow.